Related Experiment Video

Updated: Aug 15, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K

PI3K/AKT/mTOR signaling pathway modulation by circular RNAs in breast cancer progression

Mohsen Karami Fath1, Ramtin Akhavan Masouleh2, Negin Afifi3

  • 1Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.

Pathology, Research and Practice
|December 30, 2022
PubMed

Insights

Dysregulated circular RNAs (circRNAs) activate the PI3K/Akt pathway, driving breast cancer growth and progression. Targeting these circRNAs offers a promising therapeutic strategy for breast cancer.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • The PI3K/Akt/mTOR pathway regulates critical cellular functions like survival and proliferation.
  • Circular RNAs (circRNAs) are key regulators of gene expression.
  • Aberrant PI3K/Akt signaling is implicated in various cancers, including breast cancer.

Purpose of the Study:

  • To review the role of PI3K/Akt-regulating circRNAs in breast cancer.
  • To explore the correlation between these circRNAs and clinical features of breast cancer.
  • To discuss the potential of circRNAs as diagnostic biomarkers and therapeutic targets.

Main Methods:

  • Literature review of studies on circRNAs and the PI3K/Akt pathway in breast cancer.
  • Analysis of correlations between circRNA dysregulation and breast cancer clinical parameters.
  • Evaluation of therapeutic strategies targeting circRNAs.

Main Results:

  • Upregulation of the PI3K/Akt pathway by dysregulated circRNAs promotes breast tumor initiation and progression.
  • PI3K/Akt-regulating circRNA dysregulation correlates with overall survival, tumor size, cancer stage, and lymph node metastasis.
  • Targeting these circRNAs shows potential for cancer therapy.

Conclusions:

  • PI3K/Akt-regulating circRNAs are significantly involved in breast cancer pathogenesis.
  • These circRNAs may serve as valuable diagnostic and prognostic biomarkers.
  • Targeting the circRNA-PI3K/AKT axis presents a novel therapeutic avenue for breast cancer treatment.
Keywords:
BiomarkerBreast cancerCancer-targeted therapyCircular RNAPI3K/Akt/mTOR pathway

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.3K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K